Bayer's Balance-Sheet Pivot: Debt Target Slashed as Crop Science Carries the Quarter
Published on 08/05/2026 at 16:43 | Redaktion boerse-global.de
Bayer's second-quarter numbers, released on Tuesday, did more than just restore the German conglomerate to profitability — they gave investors a fresh framework for measuring the company's financial rehabilitation. The group swung to a net profit of €219 million, reversing a €199 million loss in the same period last year, while management used the occasion to pull its year-end net financial debt target down to a range of €29–30 billion, a meaningful tightening from the previous €32–33 billion guidance.
The market response was immediate. Bayer shares climbed 2.73% on Wednesday to €49.72, extending a rally that had already delivered a 4.65% gain the prior week. The stock now sits roughly 7.69% below its 52-week high of €53.86, a level touched in early July shortly after the US Supreme Court ruled in the company's favor on Roundup labeling — a decision that has reshaped the legal risk calculus for the shares.
Crop Science Delivers the Muscle
Group revenue rose 2.2% on a currency- and portfolio-adjusted basis to €10.872 billion, with adjusted EBITDA improving 1.9% to €2.144 billion. The standout performance came from the Crop Science division, where adjusted EBITDA surged 30.2% to €902 million, supported by higher glyphosate prices and the regulatory approval of Dicamba. The agricultural unit posted a 31% EBITDA margin for the first half of the year.
Pharmaceuticals painted a more mixed picture. Division earnings slipped 3.6%, as patent expirations continued to weigh on established products: Xarelto sales dropped 42% and Eylea fell 33%, both under pressure from biosimilar competition. The newer portfolio partially offset those declines, with the prostate cancer drug Nubeqa generating quarterly sales of €820 million, up from €546 million a year earlier.
Should investors sell immediately? Or is it worth buying Bayer?
The quarter also marked the first reporting period under new CFO Judith Hartmann, who took office on June 1. Management confirmed its full-year currency-adjusted guidance, targeting revenue between €45 billion and €47 billion and adjusted EBITDA of €9.6–10.1 billion for 2026.
Debt Reduction Accelerates
The lowered debt target reflects a combination of operational improvement and balance-sheet maneuvers. Net financial debt stood at €33.6 billion at the last reading, but the company has been actively chipping away at that figure. Private equity firm Apollo is injecting €3 billion, and Bayer has placed a $5 billion bond. CEO Bill Anderson has also pushed back against speculation about a potential breakup, insisting the company will continue its restructuring along five defined priorities rather than pursue a split.
Legal Calendar Takes Center Stage
The Supreme Court's June ruling in the "Durnell" case has strengthened Bayer's hand in its long-running glyphosate litigation. The company is now preparing for a hearing on August 19 in Missouri regarding a proposed class settlement that could total up to $7.25 billion, spread over 21 years. For investors, the appeal of a comprehensive settlement is straightforward: it would replace the unpredictable drip of individual verdicts with a defined cost structure.
Analysts have responded favorably to the combination of restored profitability, reduced debt ambitions, and legal progress. Deutsche Bank initiated coverage with a "Buy" rating on Wednesday, while UBS reaffirmed its own "Buy" stance the same day. JPMorgan's Richard Vosser characterized the results as strong, pointing to rising earnings expectations for the group.
Bayer at a turning point? This analysis reveals what investors need to know now.
A Stock in Recovery Mode
The share price trajectory tells the story of a steady rehabilitation. Year-to-date, Bayer is up 34.34%, and the stock trades well above its 200-day moving average of €39.53 — a technical indicator that underscores the durability of the current uptrend. The broader DAX index also notched a record close on Tuesday at 26,202 points, rising 0.8%, with Bayer among the session's gainers.
The immediate catalyst calendar is now clear. The August 19 hearing will test whether the legal tailwind translates into a binding agreement, while the next scheduled milestone arrives on November 3 with the third-quarter report. Between those two dates, investors will be watching whether the company can sustain the operational momentum that has finally given the turnaround narrative some tangible evidence to stand on.
Ad
Bayer Stock: New Analysis - 5 August
Fresh Bayer information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
